This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00105/identifier/uniprotkb/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00105/identifier/pharmgkb/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://www.rxlist.com/cgi/generic/
n5http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00105/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00105/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00105
rdf:type
n3:Drug
n3:description
Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
n3:dosage
n17:271B45A1-363D-11E5-9242-09173F13E4C5 n17:271B45A2-363D-11E5-9242-09173F13E4C5 n17:271B45A3-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR: Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure. 1996 Dec 15;4(12):1453-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8994971
n3:group
approved
n3:halfLife
The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.
n3:indication
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
owl:sameAs
n14:DB00105 n22:DB00105
dcterms:title
Interferon Alfa-2b, Recombinant
adms:identifier
n9:PA164783990 n10:P01563 n11:0085-0571-02 n12:DB00105
n3:mechanismOfAction
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
n3:packager
n20:271B459A-363D-11E5-9242-09173F13E4C5 n20:271B459B-363D-11E5-9242-09173F13E4C5 n20:271B4599-363D-11E5-9242-09173F13E4C5
n3:patent
n5:1341567 n5:2201749
n3:synonym
rIFN-alpha-2b Interferon alfa-2b
n3:toxicity
There is limited experience with overdosage. Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose. In general, the primary effects of an overdose are consistent with the effects seen with therapeutic doses of interferon alfa-2b. Hepatic enzyme abnormalities, renal failure, hemorrhage, and myocardial infarction have been reported with single administration overdoses and/or with longer durations of treatment than prescribed. Toxic effects after ingestion of interferon alfa-2b are not expected because interferons are poorly absorbed orally.
n18:hasAHFSCode
n21:08-18-20
n3:foodInteraction
Avoid alcohol.
foaf:page
n16:introna.htm
n3:Molecular-Formula
n6:271B45A8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B45A7-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:L03AB05
n3:absorption
Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
99210-65-8
n3:category
n3:containedIn
n4:271B45A0-363D-11E5-9242-09173F13E4C5 n4:271B459E-363D-11E5-9242-09173F13E4C5 n4:271B459F-363D-11E5-9242-09173F13E4C5 n4:271B459C-363D-11E5-9242-09173F13E4C5 n4:271B459D-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n6:271B45A5-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n6:271B45A6-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B45A4-363D-11E5-9242-09173F13E4C5